# Balance Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/balance-therapeutics

- Industry: Pharmaceuticals
- Headquarters: San Bruno, US
- Website: www.balance-therapeutics.com
- Total disclosed funding: $18M
- Latest round: Series B (Mar 5, 2015)
- Investors on record: 3

## About

Balance Therapeutics, Inc. develops therapeutic solutions aimed at addressing complex neurological disorders, offering innovative approaches to treatment through advanced technology and research.Founded in 2009, Balance Therapeutics, Inc. is headquartered in San Bruno, US, focusing on developing treatments for neurological conditions. The company has successfully completed 9 deals, with the most recent funding round being a Series C that raised USD 21.9 mn on February 17, 2016. The firm was founded by Craig Garner, who has a history of entrepreneurial ventures in the healthcare sector. Balance Therapeutics has raised a total of USD 21.9 mn, reflecting its commitment to advancing its therapeutic offerings.Balance Therapeutics, Inc. specializes in developing therapeutic solutions designed to treat various neurological disorders. Their core offerings include innovative therapies that leverage cutting-edge research to improve patient outcomes and enhance the standard of care. The products are developed with a focus on efficacy and safety, targeting healthcare providers looking for effective treatment solutions for their patients. Balance's therapies are available in multiple regions, including North America and Europe, expanding their reach to various healthcare systems.Balance Therapeutics, Inc. generates revenue primarily through partnerships and collaborations with healthcare organizations, focusing on the commercialization of their therapeutic solutions. Their pricing model is structured to accommodate healthcare providers, allowing for tailored agreements based on the specific needs of institutions. The firm’s innovative therapeutic solutions are critical in supporting revenue generation, with a business model designed to align with the healthcare sector’s financial frameworks.Balance Therapeutics, Inc. aims to expand its product line with new therapies currently in development, set to launch in the next 18 months. The company is targeting expansion into European markets by 2025, focusing on partnerships with local healthcare providers to facilitate entry. The recent Series C funding of USD 21.9 mn will support these initiatives, ensuring that the company has the resources needed for product development and market outreach.

## Funding rounds

- Series B, Mar 5, 2015, $18M — Mohr Davidow Ventures, Pappas Capital, Stanford University
- Series A, Jan 1, 2011 — Mohr Davidow Ventures, Pappas Capital, Stanford University

## Investors

- Mohr Davidow Ventures (https://capitalatlas.ai/funds/mohr-davidow-ventures) — Series A, Series B
- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series A, Series B
- Stanford University — Series A, Series B